Interchangeability among carbamazepine formulations
the impact over epilepsy patients
DOI:
https://doi.org/10.1590/s2175-97902022e19594Keywords:
Antiepilepticdrugs, Carbamazepine, Epilepsy, Genericmedications, InterchangeabilityAbstract
The treatment of epilepsy is complex and a matter of concern is the interchangeability among different formulations available for antiepileptic drugs. To evaluate the effects of interchangeability among carbamazepine formulations on patients with epilepsy. This is a prospective cohort study that included adult outpatients diagnosed with epilepsy and under pharmacological treatment with carbamazepine. Before switching the brand/manufacturer, the “Interchangeable Pharmaceutical Product in the Treatment of Epilepsies” questionnaire was applied. The questionnaires “Adverse Events Profile” and Quality of Life in Epilepsy-31, so as the plasma carbamazepine concentrations, were evaluated before and after the brand/ manufacturer switch. Physical-chemical tests aiming to assess tablets quality were performed in accordance with the Brazilian Pharmacopoeia 5th edition. The study population was composed by 14 patients (mean age: 44.6 years), with 10 of females. From those interviewed, 10 had no knowledge about the three antiepileptic drugs formulations available. The frequency of adverse event “problems with skin” incresead (p=0.023) and “upset stomach” decreased (p=0.041) after the changeover. The adverse events profile was associated with only two quality of life domains: “energy/fatigue” (p=0.048) and “total score” (p=0.018). Divergent results between generic and reference formulations were observed in purity-water test (reference: 1.96%, generic: 4.84%) and dissolution test, in which the generic formulation presented 66.27 to 85.77% of carbamazepine dissolved after the third level.
Downloads
References
Al Ameri MN, Nayuni N, Kumar KGA, Perrett D, Tucker A, Johnston A. The differences between the branded and generic medicines using solid dosage forms: In-vitro dissolution testing. Results Pharma Sci. 2012;2:1-8.
Atif M, Azeem M, Sarwar MR. Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literature. Springer Plus. 2016;5(82):1-8.
Brasil. Farmacopeia Brasileira. 5a edição. Brasília: AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA, 2010a. 548p. v.1.
Brasil. Farmacopeia Brasileira . 5a edição. Brasília: AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA , 2010b. 546p. v.2.
Brasil. Lei nº. 8.666, de 21 de junho de 1993. Regulamenta o art. 37, inciso XXI, da Constituição Federal, institui normas para licitações e contratos da Administração Pública e dá outras providências. Diário Oficial da União, Brasília, seção 1, p.8269, 22 de junho de 1993.
Brasil. Portaria n0 3.916, de 30 de outubro de 1998. Dispõe sobre a aprovação da Política Nacional de Medicamentos. Diário Oficial da República Federativa, Brasília, 30 outubro de 1998.
Da Silva TI, Ciconelli RM, Alonso NB, Azevedo AM, Westphal-Guitti AC, Pascalicchio TF, et al. Validity and reliability of the Portuguese version of the quality of life in epilepsy inventory (QOLIE-31) for Brazil. Epilepsy Behav. 2007;10(2):234-241.
Desmarias JE, Beauclair L, Margolese HC. Switching from Brand-Name to Generic Psychotropic Medications: A Literature review. CNS Neurosci Ther. 2011;17(6):750-760.
Euen BJ, Fadda HM. Community pharmacists’ understanding and perceptions of FDA therapeutic equivalence standards. Res Social Adm Pharm. 2019;15(1):77-83.
Flicker F, Eberle VA, Betz G. Variability in commercial carbamazepine samples - Impact on drug release. Int J Pharm. 2011;410(1-2):99-106.
Gierbolini J, Giarratanob M, Benbadisc SR. Carbamazepine- related antiepileptic drugs for the treatment of epilepsy - a comparative review. Expert Opin Pharmacother. 2016;17(7):885-8.
Guilhoto LMFF, Alexandre V, Martins HH, Santos CM, Lin K, Silva ARCO, et al. Há riscos na utilização de diferentes formulações de drogas antiepilépticas? Relato da ABE através de entrevista de pessoas com epilepsia. J Epilepsy Clin Neurophysiol. 2009;15(1):41-49.
Hensler K, Uhlmann C, Porschen T, Benecke R, Rosche J. Generic substitution of antiepileptic drugs - A survey of patients` perspectives in Germany and other German- speaking countries. Epilepsy Behav . 2013;27(1):135-139.
Jankovic SM, Ristic DI. Is bioavailability altered in generic versus brand anticonvulsants? Expert Opin Drug Metab Toxicol. 2017;11(3):329-332.
Jarvie D, Mahmoud SH. Therapeutic Drug Monitoring of Levetiracetam in Select Populations. J Pharm Pharm Sci. 2018;21(1s):149s-176s.
Krauss GL, Caffo B, Chang YT, Hendrix CW, Chuang K. Assessing bioequivalence of generic antiepilepsy drugs. Ann Neurol. 2011;70(2):221-228.
Lancker GV, Bortel LV, Delafontaine B, Boussery K, Swart E, Chahbouni A, et al. Switchability of gabapentin formulations: a randomized trial to assess bioequivalence between neurontin and gabasandoz on the individual subject level. Clin Pharmacol Ther. 2019;106(1):195-202.
Lang JD, Kostev K, Onugoren MD, Gollwitzer S, Graf W, Muller T, et al. Switching the manufacturer ofantiepileptic drugs is associated withhigher risk of seizures: a nationwidestudy of prescription data in Germany. Ann Neurol. 2018;84(6):918-925.
Lopes RA, Neves FAR. Metanálise de estudos de bioequivalência: a intercambiabilidade de genéricos e similares que contêm Hidroclorotiazida é possível, mas não àqueles com Maleato de Enalapril. J Bras Nefrol. 2010;32(2):173-181.
Martins HH, Alonso NB, Vidal-Dourado M, Carbonel TD, de Araújo Filho GM, Cabloco LO, et al. Are adverse effects of antiepileptic drugs diferente in symptomatic partial and idiopathic generalized epilepsies? The Portuguese-Brazilian validation of the Liverpool Adverse Events Profile. Epilepsy Behav . 2011;22(3):511-517.
Medina JR, Salazar DK, Hurtado M, Cortés AR, Domínguez- Ramírez AM. Comparative in vitro dissolution study of carbamazepine immediate-release products using the USP paddles method and the flow-through cell system. Saudi Pharm J. 2014;22(2):141-147.
Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Comission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239-1276.
Perucca E, Albani F, Capovilla G, Bernardina BD, Michelucci R, Zaccara G. Recommendations of the Italian league against epilepsy working group on generic products of antiepileptic drugs. Epilepsia. 2006;47(S.5):16-20.
Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. The lancet neurology. 2012;11(9):792-802.
Prasaja B, Harahap Y, Lusthom W, Hardiyanti Sinandang T, Yusvita LY, et al. Comparative bioavailaibilty of two valproic acid delayed-release tablets in healthy volunteers with tighter acceptance criteria to anticipate breakthrough seizures. Pharm Sci Asia. 2019;46(1):12-18.
Queiroz MEC, Silva SM, Carvalho D. Simultaneous determination of six antiepileptic drugs by high-performance liquid chromatograph. Rev Bras Toxicol. 2000;13(2):35-40.
Rahman MM, Alatawi Y, Cheng N, Qian J, Plotkina AV, Peissiq PL, et al. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Epilepsy Res. 2017;135:71-78.
Stepanova D, Beran RG. The benefits of antiepileptic drug (AED) blood level monitoring to complement clinical management of people with epilepsy. Epilepsy Behav . 2015;42:7-9.
Tavares G, Pires CC, Souza JD, Tasso L. Avaliação do polimorfismo e Perfil de Dissolução de Formulações de Carbamazepina. Sci Cum Ind. 2016;4(3):161-166.
Terra LA, Poppi RJ. Monitoring the polymorphic transformation on the surface of carbamazepine tablets generated by heating using near-infrared chemical imaging and chemometric methodologies. Chemom Intell Lab Syst. 2014;130:91-97.
Trinka E, Kramer G, Graf M. Requirements for generic antiepileptic medicines: a clinical perspective. J Neurol. 2011;258(12):2128-2132.
Winter ME. Part 1 Basic Principles-Maximum and Minimum Plasma Concentrations. In: WINTER, M. E. Basic Clinical Pharmacokinetics. India: Wolters Kluwer Health, 2009, p.54-57.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
